Clinical nonmotor aspect of A2A antagonist in PD treatment

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 191-194

  Nomoto, Masahiro ^a   Nagai, Masahiro ^a   Nishikawa, Noriko ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Istradefylline; Nonmotor functions; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; DICLOFENAC; DOPA DECARBOXYLASE INHIBITOR; ISTRADEFYLLINE; LEVODOPA; LOXOPROFEN; PRAMIPEXOLE; SELEGILINE; ZONISAMIDE; ADENOSINE A2 RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BRADYKINESIA; CASE REPORT; DAILY LIFE ACTIVITY; DEPRESSION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXHAUSTION; FATIGUE; FEMALE; HALLUCINATION; HOEHN AND YAHR SCALE; HUMAN; LEG PAIN; LIMB TREMOR; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; COMPLICATION; HALLUCINATIONS;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; DEPRESSION; FATIGUE; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84906728064     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00009-X     Document Type: Chapter

References (4)

1. 2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003, 61(11 Suppl. 6):S97-S100.
2. 2A receptor antagonist istrdefilline reduced daily OFF time in Parkinson's disease. Movement Disorders 2013, 28:1138-1141.
3. Nomoto M., Kaseda S., Iwata S., Shimizu T., Fukuda T., Nakagawa S. The metabolic rate and vulnerability of dopaminergic neurons, and adenosine dynamics in the cerebral cortex, nucleus accumbens, caudate nucleus, and putamen of the common marmoset. Journal of Neurology 2000, 247(Suppl. 5):V16-V22.
4. 2A antagonist istradefylline, in the forced swim test and the tail suspension test in rodents. Pharmacology, Biochemistry, and Behavior 2013, 114-115:23-30.